Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $18.54 million. The enterprise value is $4.54 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 8.03 million shares outstanding. The number of shares has increased by 0.48% in one year.
| Current Share Class | 8.03M |
| Shares Outstanding | 8.03M |
| Shares Change (YoY) | +0.48% |
| Shares Change (QoQ) | +4.95% |
| Owned by Insiders (%) | 4.64% |
| Owned by Institutions (%) | 14.58% |
| Float | 6.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.62 |
| Forward PS | 46.62 |
| PB Ratio | 1.01 |
| P/TBV Ratio | 1.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.68, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.68 |
| Quick Ratio | 6.36 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.28% and return on invested capital (ROIC) is -36.09%.
| Return on Equity (ROE) | -54.28% |
| Return on Assets (ROA) | -32.81% |
| Return on Invested Capital (ROIC) | -36.09% |
| Return on Capital Employed (ROCE) | -71.64% |
| Weighted Average Cost of Capital (WACC) | 10.02% |
| Revenue Per Employee | $141,191 |
| Profits Per Employee | -$687,679 |
| Employee Count | 14 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $200 in taxes.
| Income Tax | 200 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.84% in the last 52 weeks. The beta is 1.09, so Lipocine's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | -28.84% |
| 50-Day Moving Average | 6.17 |
| 200-Day Moving Average | 4.83 |
| Relative Strength Index (RSI) | 30.04 |
| Average Volume (20 Days) | 1,019,727 |
Short Selling Information
The latest short interest is 154,115, so 1.92% of the outstanding shares have been sold short.
| Short Interest | 154,115 |
| Short Previous Month | 143,656 |
| Short % of Shares Out | 1.92% |
| Short % of Float | 2.41% |
| Short Ratio (days to cover) | 0.18 |
Income Statement
In the last 12 months, Lipocine had revenue of $1.98 million and -$9.63 million in losses. Loss per share was -$1.77.
| Revenue | 1.98M |
| Gross Profit | 1.98M |
| Operating Income | -10.37M |
| Pretax Income | -9.63M |
| Net Income | -9.63M |
| EBITDA | -10.31M |
| EBIT | -10.37M |
| Loss Per Share | -$1.77 |
Full Income StatementBalance Sheet
The company has $14.93 million in cash and $449,591 in debt, giving a net cash position of $14.48 million or $1.80 per share.
| Cash & Cash Equivalents | 14.93M |
| Total Debt | 449,591 |
| Net Cash | 14.48M |
| Net Cash Per Share | $1.80 |
| Equity (Book Value) | 14.48M |
| Book Value Per Share | 2.35 |
| Working Capital | 14.35M |
Full Balance SheetCash Flow
| Operating Cash Flow | -9.76M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 60,782 |
| Net Borrowing | n/a |
| Free Cash Flow | -9.76M |
| FCF Per Share | -$1.22 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -524.69% |
| Pretax Margin | -487.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |